Tenax Therapeutics, Inc. financial data

Symbol
TENX on Nasdaq
Industry
Pharmaceutical Preparations
Location
101 Glen Lennox Drive, Suite 300, Chapel Hill, NC
State of incorporation
DE
Fiscal year end
December 31
Former names
OXYGEN BIOTHERAPEUTICS, INC. (to 9/15/2014), SYNTHETIC BLOOD INTERNATIONAL INC (to 6/30/2008)
Latest financial report
10-K - Q4 2024 - Mar 25, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.01K % +128%
Debt-to-equity 5.24 % -59.1%
Return On Equity -33.4 % +49.2%
Return On Assets -31.8 % +45.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.97M shares +103%
Common Stock, Shares, Outstanding 3.42M shares +1047%
Entity Public Float 5.89M USD -16.3%
Common Stock, Value, Issued 0 USD

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 12.7M USD +294%
General and Administrative Expense 6.79M USD +35.6%
Operating Income (Loss) -19.5M USD -137%
Net Income (Loss) Attributable to Parent -17.6M USD -128%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 94.9M USD +868%
Other Assets, Current 64K USD -74.6%
Assets, Current 96.7M USD +728%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 0 USD -100%
Assets 96.7M USD +727%
Accounts Payable, Current 3.16M USD +52.3%
Employee-related Liabilities, Current 1.34M USD +72.4%
Accrued Liabilities, Current 1.54M USD +51.6%
Liabilities, Current 4.69M USD +30.8%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 4.69M USD +30.8%
Retained Earnings (Accumulated Deficit) -315M USD -5.92%
Stockholders' Equity Attributable to Parent 92M USD +1036%
Liabilities and Equity 96.7M USD +727%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.72M USD +41.3%
Net Cash Provided by (Used in) Financing Activities 7.92M USD -43.5%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 3.42M shares +1047%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 94.9M USD +869%
Deferred Tax Assets, Valuation Allowance 41.7M USD +7.82%
Operating Lease, Liability 0 USD -100%
Depreciation 6.57K USD +53.3%
Payments to Acquire Property, Plant, and Equipment 1.24K USD -80.4%
Deferred Tax Assets, Operating Loss Carryforwards 37.6M USD +2.18%
Additional Paid in Capital 407M USD +33.2%
Preferred Stock, Shares Outstanding 5.18M shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 23K USD -4.17%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares